中國生命集團(08296.HK)一季度淨利72.2萬元 同比減少72.83%
格隆匯5月13日丨中國生命集團(08296.HK)公佈,截至2022年3月31日止三個月(第一季度),公司收益為人民幣2058萬元,同比增長8.54%;公司擁有人應占期間溢利為人民幣72.2萬元,同比減少72.83%;每股盈利為人民幣0.10分。
集團已形成以傳統殯儀服務及新興生物科技為主的業務格局。雖然目前傳統殯儀服務業務佔集團業務比重比較大,且集團收益主要來自中國市場,但生物科技仍是本集團拓展其業務的長期重點。
目前,集團主要涉足幹細胞及高端生物科技儀器等細分領域,並取得實質性進展。由於中國內地幹細胞應用政策尚未完全放開,幹細胞業務尚未形成大規模發展。為避免對集團整體經營業績產生任何不利影響,集團短期內將減少對幹細胞業務的投資。隨着歐洲經濟活動逐步恢復,集團的歐洲供應商已加快復工復產。集團將充分發揮資源優勢,抓住中國內地電子顯微鏡行業快速發展的機遇,從而進一步擴大高端生物科技儀器業務規模。
此外,為進一步推動生物科技業務的快速發展,集團於2021年12月建立了專業化、綜合性的投資平台,主要專注於生物科技產業發展方向的投資,包括但不限於生物醫藥、醫療保健、生命科學儀器等,以及可以產生協同效應的新興產業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.